Johnson and Johnson Company - Search News

Johnson & Johnson Dips On Q4 Earnings

Hosted on MSN · 20h

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings

Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the look-back and look-ahead on an earnings call,

Barron's on MSN · 21h

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth

Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its top-selling medicines, Stelara, to go off patent in the coming weeks.Fourth-quarter sales,

The Motley Fool on MSN · 1d

Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript

Operator Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

Seeking Alpha · 19h

Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.

Zacks.com on MSN · 23h

Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.

22h

Johnson & Johnson Tops Q4 EPS Forecasts

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

1d

Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

The Dallas Company That Could End an $8 Billion Johnson & Johnson Talc Powder Lawsuit

This fall, pharmaceutical and medical technology company Johnson & Johnson announced that a newly created Dallas subsidiary ...

TipRanks on MSN3d

Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards

Staying ahead of the competition is critical in every sector, particularly in the dynamic healthcare space, where a single ...

1d

Johnson & Johnson (JNJ) Receives a Hold from Morgan Stanley

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...

MarketBeat on MSN5d

Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

Johnson & Johnson (NYSE: JNJ) stock is up 1.8% in the five days after the company announced its $14.6 billion acquisition of ...

6don MSN

Johnson & Johnson's SWOT analysis: stock outlook amid pipeline progress, biosimilar challenges

Johnson & Johnson (NYSE:JNJ), a global healthcare leader, finds itself at a pivotal juncture as it navigates a landscape of ...

5d

3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond

Dividend cuts can be devastating to an income-focused investor. You lose a portion of your passive income, and a dividend ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results